The Lancet publishes results from phase III program evaluating Rinvoq in atopic dermatitis. - AbbVie.

The results were published in two separate manuscripts as part of the May 22, 2021 issue of The Lancet. The publication of Measure Up 1 and Measure Up 2 shares efficacy and safety results of patients treated with upadacitinib (15 mg or 30 mg, once daily) monotherapy versus placebo for 16 weeks. The publication of AD Up shares efficacy and safety results of patients treated with either dose of Rinvoq met all primary and secondary endpoints. See- "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials"..Emma Guttman-Yassky, MD,Henrique D Teixeira, PhD, Eric L Simpson, MD, Kim A Papp, MD, Aileen L Pangan, MD Andrew Blauvelt, MD et al.-Published:May 20, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00588-2. " Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial".- Prof Kristian Reich, MD , Henrique D Teixeira, PhD, Marjolein de Bruin-Weller, MD, Prof Thomas Bieber, MD, Weily Soong, MD ,Prof Kenji Kabashima, MD ,et al.Published:May 20, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00589-4.